I'm so happy for today's news! To maximize the financial potential and increase the company's valuation, I hope the company will pursue a route for long-term treatment of COVID-19 as well.

It has been shown that long-haulers still have some residual infection in them, even after the apparently recovery. So, this residual infection makes them sick or to have "post-COVID-19 syndrome", which gets better very slowly, if at all. When these patients took vaccine, they actually got better.

RVX has unique MoA that makes dorman cells in HIV patients to be active again. Once these cells become active, they can be targeted by antivirals. Likewise, the company should test if RVX can do the same for the cells infected with COVID-19, ie. make the infected cells active again and prone to attacks from a cocktail of antivirals.

The approval for the acute treatment will be huge. But, this long-term treatment route will put the RVX into whole another level.